Comparative Pharmacology
Head-to-head clinical analysis: BETIMOL versus LOPRESSOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETIMOL versus LOPRESSOR.
BETIMOL vs LOPRESSOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonselective beta-adrenergic receptor antagonist; reduces intraocular pressure by decreasing aqueous humor production.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors, predominantly in cardiac tissue.
1 drop of 0.25% or 0.5% solution in the affected eye(s) twice daily. If inadequate response, increase to 0.5% solution twice daily.
50 mg orally twice daily, titrate up to 100 mg twice daily as needed.
None Documented
None Documented
2.5 to 5 hours (average 4 hours) in patients with normal renal function; may be prolonged in renal impairment (up to 8-10 hours).
Terminal elimination half-life: 3-7 hours (mean 4.5 h); may be prolonged in hepatic impairment or elderly
Primarily renal (unchanged drug and metabolites). Approximately 60-80% of a dose is excreted renally as unchanged timolol, with the remainder as inactive metabolites. Biliary/fecal excretion accounts for less than 20%.
Renal: ~95% (primarily as metabolites, <5% unchanged); fecal: ~5%
Category C
Category C
Beta-Blocker
Beta-Blocker